Fewer Cycles of Oxaliplatin Treatment May Reduce Incidence of Severe Neuropathy for Patients With Stage III Colon CancerNovember 29th 2022
An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA AlterationsNovember 14th 2022
Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.
Aggressive HER2-Targeted Therapy May Have a Role Following Disease Progression in Patients With Breast Cancer and Brain MetastasesNovember 2nd 2022
Patients with HER2-positive breast cancer and brain metastases experienced a median progression-free survival of 8 months and a median overall survival of 14 months with HER2-targeted therapy.
Phosphorous Monitoring May Be Optimal for Detecting Serious ICANS in Patients Receiving CAR T-Cell TherapyOctober 31st 2022
Following CAR T-cell therapy, the onset of hypophosphatemia may represent a biomarker for immune effector cell–associated neurotoxicity syndrome incidence and severity.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPCOctober 29th 2022
A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.
5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck CancerOctober 28th 2022
A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.
Sri Kota Puts the Nursing Lens On Recent Data With Sacituzumab Govitecan in TROPiCs-02October 26th 2022
Sri Kota, MSN, BA, RN, OCN, unpacks data from the phase 3 TROPiCS-02 trial and highlights what nurses should know about sacituzumab govitecan for patients with advanced hormone receptor–positive, HER2-negative breast cancer.
Pembrolizumab Continues to Boost Overall Survival in Patients with Head and Neck Cancer at 4-Year Follow-UpOctober 21st 2022
The overall survival benefit associated with pembrolizumab for patients with head and neck cancer continued to be observed at a 4-year follow-up of the KEYNOTE-048 trial.
Mirvetuximab Soravtansine Associated with Fewer GI Toxicities Than Chemotherapy in Advanced Ovarian CancerOctober 18th 2022
An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.
Later Toxicities Linked to Bone Marrow Transplant Highlight Necessity of Thorough Survivorship Care for Patients With AMLOctober 14th 2022
Individuals with AML who underwent a bone marrow transplant are at an increased risk of developing subsequent neoplasms, and other chronic health conditions.
Investigators Identify Immunotherapy Followed by BRAK/MEK Inhibition as Optimal Sequence Strategy in BRAF+ MelanomaOctober 11th 2022
Optimal treatment sequencing for patients with BRAF-mutated melanoma involves frontline immunotherapy following by BRAF/MEK inhibition, according to investigators.
Dose Reductions Help Patients with Breast Cancer Stay on Abemaciclib LongerOctober 11th 2022
At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.
Oral SERD Elacestrant Shows Significant PFS Improvement in ER+/HER2– Advanced Breast CancerOctober 6th 2022
Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer.
Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract CancersOctober 4th 2022
Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.
Niraparib, Olaparib, and Rucaparib No Longer Available for Patients with Heavily Pretreated, BRCA-Mutated Advanced Ovarian CancerOctober 2nd 2022
Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.